Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DehydraTECH, the most common co-covered peer. We currently track 1 Biotech story that mention SNAC (salcaprozate sodium), all published on July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DehydraTECH, the most common co-covered peer. We currently track 1 Biotech story that mention SNAC (salcaprozate sodium), all published on July 12, 2026. Each carries 4 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SNAC (salcaprozate sodium). Shared-story counts are live from our verified record — not editorial picks.
Lexaria Bioscience commenced dosing in its GLP-1 animal study aiming to outperform Novo Nordisk’s SNAC-based oral delivery. With 11 arms and three new patent filings, the biotech targets differentiation in the booming GLP-1 sector.
SNAC (salcaprozate sodium) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
